
According to Adam Alexander, OD, Miebo can make headway in establishing a need for precision medication when it comes to dry eye treatment.

According to Adam Alexander, OD, Miebo can make headway in establishing a need for precision medication when it comes to dry eye treatment.

The company plans to finalize its Phase 3 development plans following an End-of-Phase 2 meeting with the FDA.

Researchers examined data of more than 200,000 people, 121,523 of which had no history of AMD.

The silicone hydrogel daily disposable lenses contain a blend of osmoprotectants, electrolytes, and moisturizers to provide stable vision and keep eyes comfortable for 16 hours.

Harmonize your vision in Nashville.

The company currently has CooperVision and Bausch + Lomb contact lenses available for customers to order.

LGBTQ patients are more at risk for not receiving health care due to fear of discrimination.

The French study found that a complete capsular removal seemed to be the safer option for pediatric patients with Marfan syndrome in terms of risk of retinal detachment.

Catch up on what happened in optometry during the week of June 3-June 7.

The solution, CAM360 AmnioGraft, is hydrated and shelf-stable without need for refrigeration.

Award winners will be announced at the NORA 2024 Conference from September 19-22 in Kissimmee, Florida.

The trial, in part of the ASTRO study, will evaluate the efficacy, safety, and tolerability of sterile ophthalmic ointment 0.5%.

One of the resources provided by the partnership is a Dry Eye Wheel, which provides mitigation, measurement, and management processes to inform the treatment of dry eye disease.

The study demonstrated sustained safety and efficacy of cyclosporine ophthalmic solution (Vevye) 0.1%, with many patients now entering their sixth refill cycle, according to the company.

The high-level analysis found in treatment follow-up that 82% of patients administered with TEPEZZA did not report needing any additional thyroid eye disease treatment for nearly 2 years.

The biotechnology company is developing the first protein-based artificial retina for patients with retinitis pigmentosa and age-related macular degeneration.

The novel therapy for dry eye is a cross-linked hyaluronic acid derivative cleared by the FDA.

The launch of the nutritional supplement follows a clinical trial that demonstrated healthy tear production and provided noticeable relief of dry eye symptoms in as little as 2 to 4 weeks.

The pachymeter is the most lightweight handheld product of its kind on the market, according to the company.

Catch up on what happened in optometry during the week of May 27-May 31.

The company’s initiatives include involvement with the Global Myopia Awareness Coalition and discounting blue light screen protectors and its pediatric eye care program, among others.

InflammaDry is a diagnostic test that detects elevated levels of MMP-9, an inflammatory marker consistently found in the tears of patients with DED.

The COAST and ShORe trials have a total of 1984 patients enrolled for the treatment of wet age-related macular degeneration.

MyopiaX is a non-invasive, light-based treatment that uses a virtual reality headset to deliver treatment while patients engage with digital content.

The rabbit model found that the levels of the active metabolites were very comparable, whether or not eyes had received a prior installation of perfluorohexyloctane.

The study evaluated the effects of long-term, low-dose aspirin administration in over 3000 older adults.

Conjunctivitis was the only symptom identified in the second reported case.

Catch up on what happened in optometry during the week of May 20-May 24.

The Tono-Vera Tonometer allows for automated IOP measurements and eliminates the need for a topical anesthetic.

Representatives from CooperVision and the International Agency for the Prevention of Blindness give a preview of what to expect at the "Universal Access to Glasses: Promoting Multisectoral Action" event at this year's World Health Assembly in Geneva, Switzerland.